A Phase II study of MGCD0103 (MG-0103) in patients with acute myelogenous leukemia/high risk MDS who are elderly and have previously untreated disease or who are adult and have relapsed/refractory disease
Randomised, Controlled, Open-Label, Multi-Centre Comparison of Thalidomide Versus High-Dose Dexamethasone for the Treatment of Relapsed Refractory Multiple Myeloma
100 项与 Pharmion GmbH 相关的临床结果
0 项与 Pharmion GmbH 相关的专利(医药)
100 项与 Pharmion GmbH 相关的药物交易
100 项与 Pharmion GmbH 相关的转化医学